Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06617936
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-25
Brief Title:
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Sponsor:
None
Organization:
None
Organization Data
Organization:
None
Class:
None
Study ID:
None
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
None
Lead Sponsor Class:
None
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None